Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung15: Dato-DXd with or without osimertinib versus platinum doublet chemotherapy after osimertinib in EGFR-mutated metastatic non-squamous NSCLC
jRCT2061240051Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised trial of datopotamab deruxtecan and osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Oct 2024; status: active, not recruiting.
02
Drugs
datopotamab deruxtecanosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061240051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240051.